NewsMeter
$118.0 million in cash and cash equivalents sat on Tenax Therapeutics' (Nasdaq: TENX) balance sheet at June 30, 2026, up from $97.6 million at December 31, 2025, with $13.4 million of the gain from warrant exercises during the quarter.
Tenax reported a net loss of $17.8 million for Q2 2026, against $10.9 million in Q2 2025, as R&D expenses nearly doubled YoY.
The company now guides cash runway through Q2 2028 and expects topline data from its Phase 3 LEVEL trial in August 2026.
R&D nearly doubles as two Phase 3 trials run concurrently R&D expenses reached $12.9 million in Q2 2026, up from $6.1 million in Q2 2025, a $6.8 million YoY increase.
Keep reading